X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs CADILA HEALTHCARE - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA CADILA HEALTHCARE FULFORD INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 398.8 20.1 1,981.8% View Chart
P/BV x 6.2 4.8 130.3% View Chart
Dividend Yield % 0.1 0.9 9.9%  

Financials

 FULFORD INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
CADILA HEALTHCARE
Mar-18
FULFORD INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs942558 168.8%   
Low Rs450362 124.5%   
Sales per share (Unadj.) Rs691.4116.3 594.5%  
Earnings per share (Unadj.) Rs11.517.9 64.1%  
Cash flow per share (Unadj.) Rs15.423.1 66.4%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.30.8 37.7%  
Book value per share (Unadj.) Rs380.085.4 444.9%  
Shares outstanding (eoy) m3.901,023.74 0.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.0 25.5%   
Avg P/E ratio x60.725.7 236.0%  
P/CF ratio (eoy) x45.319.9 228.0%  
Price / Book Value ratio x1.85.4 34.0%  
Dividend payout %17.419.6 89.1%   
Avg Mkt Cap Rs m2,714470,664 0.6%   
No. of employees `0000.411.8 3.8%   
Total wages/salary Rs m50518,545 2.7%   
Avg. sales/employee Rs Th6,073.010,072.7 60.3%   
Avg. wages/employee Rs Th1,137.41,569.1 72.5%   
Avg. net profit/employee Rs Th100.71,547.7 6.5%   
INCOME DATA
Net Sales Rs m2,696119,049 2.3%  
Other income Rs m1251,132 11.1%   
Total revenues Rs m2,822120,181 2.3%   
Gross profit Rs m-4628,475 -0.2%  
Depreciation Rs m155,388 0.3%   
Interest Rs m10911 1.0%   
Profit before tax Rs m5423,308 0.2%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m105,644 0.2%   
Profit after tax Rs m4518,292 0.2%  
Gross profit margin %-1.723.9 -7.2%  
Effective tax rate %17.724.2 73.0%   
Net profit margin %1.715.4 10.8%  
BALANCE SHEET DATA
Current assets Rs m1,73882,005 2.1%   
Current liabilities Rs m54560,720 0.9%   
Net working cap to sales %44.317.9 247.6%  
Current ratio x3.21.4 236.3%  
Inventory Days Days4873 66.3%  
Debtors Days Days498 4.4%  
Net fixed assets Rs m1283,703 0.0%   
Share capital Rs m391,024 3.8%   
"Free" reserves Rs m1,44386,421 1.7%   
Net worth Rs m1,48287,445 1.7%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m2,077180,653 1.1%  
Interest coverage x6.726.6 25.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 197.0%   
Return on assets %2.610.6 24.6%  
Return on equity %3.020.9 14.4%  
Return on capital %4.322.0 19.6%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1742,683 0.0%   
Fx outflow Rs m67311,242 6.0%   
Net fx Rs m-65631,441 -2.1%   
CASH FLOW
From Operations Rs m909,193 1.0%  
From Investments Rs m105-9,737 -1.1%  
From Financial Activity Rs m-14515 -2.7%  
Net Cashflow Rs m181-29 -622.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 8.3 45.8%  
FIIs % 0.1 5.9 1.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 11.0 192.7%  
Shareholders   4,783 44,069 10.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - PFIZER COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS